PRISM BioLab, First Half Ordinary Profit Loss Widens, Jan-Mar Ordinary Profit Loss Widens

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Wed May 14, 2025 4:30 pm JST Earnings

206A PRISM BioLab Co.,LTD 【J-GAAP】

Earnings Report

PRISM BioLab Co.,LTD <206A> [TSE Growth] announced its financial results after the market closed on May 14th (16:30). The ordinary loss (non-consolidated) for the cumulative second quarter of the fiscal year ending September 2025 (October 2024 to March 2025) expanded to a loss of 432 million yen (compared to a loss of 322 million yen in the same period last year).

In the most recent three-month period, from January to March (2Q), the ordinary loss expanded to a loss of 252 million yen (compared to a loss of 173 million yen in the same period last year). However, the operating profit/loss margin improved from -254.8% in the same period last year to -240.9%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Oct - Mar, 2024	218	-460	-432	-474	-13.1	ー	May 14, 2025	J-GAAP
YoY	－	－	－	－	－

First Half Results vs. Previous Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Guidance	ー	ー	ー	ー	－	0	Nov 14, 2024	J-GAAP
Oct - Mar, 2024 Results	218	-460	-432	-474	-13.1	0	May 14, 2025	J-GAAP
Revision Rate	－	－	－	－	－

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024	190	-448	-509	-713	-22.8	0	Nov 14, 2024	J-GAAP
Apr - Sep, 2025 Guidance	ー	ー	ー	ー	－	0	Nov 14, 2024	J-GAAP
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Sep, 2024	305	-782	-831	-1,049	-33.5	0	Nov 14, 2024	J-GAAP
Sep, 2025 Guidance	ー	ー	ー	ー	－	0	Nov 14, 2024	J-GAAP
YoY	－	－	－	－	－

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Apr - Jun, 2024	100	-209	-174	-233	-7.8	-209.0	Aug 14, 2024	J-GAAP
Jul - Sep, 2024	90	-239	-335	-480	-15.3	-265.6	Nov 14, 2024	J-GAAP
Oct - Dec, 2024	125	-236	-180	-191	-5.3	-188.8	Feb 14, 2025	J-GAAP
Jan - Mar, 2025	93	-224	-252	-283	-7.8	-240.9	May 14, 2025	J-GAAP
YoY	－	－	－	－	－